Insights Into Chronic Lymphocytic Leukemia (CLL)

Perspectives of community physicians from across the US on the management of newly diagnosed and relapsed/refractory CLL

Southwest March 17, 2021

Faculty Chair

Susan O’Brien, MD

UC Irvine Medical Center, Orange County, CA

Southeast June 24, 2021

Faculty Chair

Ian Flinn, MD

Tennessee Oncology, Nashville, TN

Southeast & Northeast July 28, 2021

Faculty Chair

John Allan, MD

Weill Cornell Medicine, New York, NY

Northeast August 26, 2021

Faculty Chair

Susan O'Brien, MD

UC Irvine Medical Center, Orange County, CA

TX, AZ, CA September 13, 2021

Faculty Chair

Steven Coutre, MD

Stanford Cancer Center, Palo Alto, CA

Midwest September 16, 2021

Faculty Chair

Sameer Parikh, MD

Mayo Clinic, Rochester, MN

Northwest November 2021

Faculty Chair

TBA

More Information

  • Virtual Series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual Series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Virtual Series
  • New York, Tennessee

More Information

  • Virtual Series
  • Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Virtual Series
  • Texas, Arizona, California

More Information

  • Virtual Series
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Minnesota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Virtual Series
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Agenda

Export meeting topics

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of chronic lymphocytic leukemia
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: acalabrutinib, ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, and BR

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors will comprise 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.